Biogen Beats Profit Estimates on Strong Spinraza Sales

Reuters2023-04-25

(Reuters) - Biogen Inc on Tuesday beat expectations for quarterly profit on strong sales of spinal muscular atrophy drug Spinraza, but said it would pause or discontinue some studies to cut costs.

At least four studies testing stroke and gene therapies and eye disorder treatment will be discontinued or put on hold to reduce research-related expenses, Biogen said in a statement.

Excluding items, Biogen earned $3.40 per share, beating estimates of $3.28 per share.

The drugmaker also reaffirmed its full-year adjusted profit forecast of $15 to $16 per share.

The company is betting on its second Alzheimer's disease treatment, Leqembi, and depression drug zuranolone to offset slowing sales of Spinraza and multiple sclerosis drug Tecfidera.

Shares of Biogen Inc slid 1.38% in premarket trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1180633480?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-04-25 19:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1180633480","market":"us","top_or_hot":-1,"title":"Biogen Beats Profit Estimates on Strong Spinraza Sales","media":"Reuters","content":"<html><head></head><body><p>(Reuters) - <a href=\"https://laohu8.com/S/BIIB\">Biogen Inc </a> on Tuesday beat expectations for quarterly profit on strong sales of spinal muscular atrophy drug Spinraza, but said it would pause or discontinue some studies to cut costs.</p><p style=\"text-align: start;\">At least four studies testing stroke and gene therapies and eye disorder treatment will be discontinued or put on hold to reduce research-related expenses, Biogen said in a statement.</p><p style=\"text-align: start;\">Excluding items, Biogen earned $3.40 per share, beating estimates of $3.28 per share.</p><p>The drugmaker also reaffirmed its full-year adjusted profit forecast of $15 to $16 per share.</p><p style=\"text-align: start;\">The company is betting on its second Alzheimer&#39;s disease treatment, Leqembi, and depression drug zuranolone to offset slowing sales of Spinraza and multiple sclerosis drug Tecfidera.</p><p>Shares of <a href=\"https://laohu8.com/S/BIIB\">Biogen Inc </a> slid 1.38% in premarket trading.</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biogen Beats Profit Estimates on Strong Spinraza Sales</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiogen Beats Profit Estimates on Strong Spinraza Sales\n</h2>\n\n<h4 class=\"meta\">\n\n2023-04-25 19:12 北京时间&nbsp;&nbsp;&nbsp;<strong>Reuters</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) - Biogen Inc  on Tuesday beat expectations for quarterly profit on strong sales of spinal muscular atrophy drug Spinraza, but said it would pause or discontinue some studies to cut costs.At ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BIIB","symbol_name":"渤健公司","start_time":0,"source_url":"","article_id":"1180633480","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1180633480","pubTimestamp":1682421144,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"(Reuters) - Biogen Inc  on Tuesday beat expectations for quarterly profit on strong sales of spinal ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BIIB":"渤健公司"},"translate_title":"Spinraza销售强劲，Biogen超出利润预期","themeId":"ec9f6f0df2b6498587e7f5318b2eff2b","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIIB":0.9},"content_text":"(Reuters) - Biogen Inc  on Tuesday beat expectations for quarterly profit on strong sales of spinal muscular atrophy drug Spinraza, but said it would pause or discontinue some studies to cut costs.At least four studies testing stroke and gene therapies and eye disorder treatment will be discontinued or put on hold to reduce research-related expenses, Biogen said in a statement.Excluding items, Biogen earned $3.40 per share, beating estimates of $3.28 per share.The drugmaker also reaffirmed its full-year adjusted profit forecast of $15 to $16 per share.The company is betting on its second Alzheimer's disease treatment, Leqembi, and depression drug zuranolone to offset slowing sales of Spinraza and multiple sclerosis drug Tecfidera.Shares of Biogen Inc  slid 1.38% in premarket trading.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":3,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1180633480"}